Neurofibromatosis Type 2

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

Selumetinib for NF2-Related Schwannomatosis

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Doxycycline in Cutaneous Schwannoma (NF2)

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Effect of Implant Position on Magnetic Resonance Image Distortion

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors